ATB200/AT2221 for Late onset Pompe disease in adults and adolescents over 12 years – first line

ATB200 co-administered with AT2221 is in development for the treatment of Pompe disease. Pompe disease is an inherited, genetic disorder which results in the deficiency of the enzyme ‘acid alpha-glucosidase’. This deficiency leads to progressive accumulation of glycogen, a type of sugar, usually stored in muscle tissues particularly around the heart, skeletal muscle and diaphragm. Enzyme replacement therapy is a recommended treatment approach.
ATB200 (cipaglucosidase alfa) is a recombinant human acid alfa glucosidase (rhGAA) enzyme that shows significantly improved uptake into muscle cells compared with algucosidase alfa at similar doses and translates into optimised glycogen reduction in disease-relevant muscles in non-clinical models. AT2221 (miglustat) is the pharmacological chaperone that stabilises and enhances the plasma exposure of ATB200, resulting in improved delivery of active enzyme to key disease-relevant tissues. If licensed, ATB200/AT2221 will offer an additional treatment option for patients with Pompe disease with potentially improved efficacy.